# EDGAR Filing Document

**Accession Number:** 0001536196
**File Stem:** 0001213900-26-023406
**Filing Date:** 2026-3
**Character Count:** 10937
**Document Hash:** ad6504a32b4a5b4b82e915bb4e961191
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-023406.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001213900-26-023406

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260304

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Can-Fite BioPharma Ltd.
- **CENTRAL INDEX KEY:** 0001536196
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36203
- **FILM NUMBER:** 26718828

**BUSINESS ADDRESS:**
- **STREET 1:** 26 BEN GURION STREET
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5257346
- **BUSINESS PHONE:** 972 39241114

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN GURION STREET
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5257346

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

001-36203

(Commission File Number)

**CAN-FITE BIOPHARMA LTD.**

(Exact name of Registrant as specified in its charter)

**26 Ben Gurion Street**

**Ramat Gan 5257346 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

The first seven paragraphs of the press release attached hereto as Exhibit 99.1, other than the fifth paragraph, are hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File Nos. [333-227753](http://www.sec.gov/Archives/edgar/data/1536196/000121390018013702/fs82018_canfitebiopharma.htm), [333-271384](http://www.sec.gov/Archives/edgar/data/1536196/000121390023031683/ea176911-s8_canfitebiopharma.htm) and [333-278525](http://www.sec.gov/Archives/edgar/data/1536196/000121390024030834/ea0203150-s8_canfitebio.htm)) and Form F-3 (File Nos. [333-236064](http://www.sec.gov/Archives/edgar/data/1536196/000121390020008630/ea120459-posam_canfitebio.htm), [333-274316](http://www.sec.gov/Archives/edgar/data/1536196/000121390023073236/ea184383-f3_canfite.htm), [333-262055](http://www.sec.gov/Archives/edgar/data/1536196/000121390022001135/ea153627-f3_canfite.htm), [333-276000](https://www.sec.gov/Archives/edgar/data/1536196/000121390023095107/ea189833-f3_canfite.htm) and [333-281872](http://www.sec.gov/Archives/edgar/data/1536196/000121390024074545/ea0211728-f3_canfite.htm)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On March 4, 2026, Can-Fite BioPharma Ltd. issued a press release entitled "Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study". A copy of this press release is furnished herewith as Exhibit 99.1.

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated March 4, 2026](ea027935901ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 4, 2026 | By: | /s/ Motti Farbstein |
|  |  | Motti Farbstein |
|  |  | Chief Executive Officer and <br> Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study**

 

*Ramat Gan, Israel – March 04, 2026* – *Can-Fite BioPharma Ltd.* (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.

The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population. No new safety signals were identified, and the safety profile was consistent with the known clinical experience of namodenoson in other oncological diseases.

The study enrolled 20 patients with advanced PDAC who had received one or more prior lines of therapy. Patients represented a high-risk population, including individuals with varying performance status and advanced metastatic disease.

Secondary endpoints included overall survival (OS) and progression-free survival (PFS). Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings.

"The favorable safety profile observed in this difficult-to-treat population supports continued clinical evaluation of namodenoson," Prof. Salomon Stemmer, a renowned oncologist and key opinion leader at the Davidoff Center, Rabin Medical Center, Israel. "We are continuing to monitor survival outcomes as data mature."

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The drug is also being evaluated in clinical trials for advanced liver cancer.

Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

**About Can-Fite BioPharma Ltd.**

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.

**Forward-Looking Statements**

This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, timing of efficacy data and prospects for generating meaningful efficacy data . All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

**Contact**

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114